Advances in Immunotherapy for Glioblastoma Multiforme. (19th February 2017)

• Record Type: Journal Article
• Authors: Huang, Boyuan; Zhang, Hongbo; Gu, Lijuan; Ye, Bainxin; Jian, Zhihong; Stary, Creed; Xiong, Xiaoxing
• Other Names: Thounaojam Menaka C. Academic Editor.
• Is Part Of: Journal of immunology research. Volume 2017(2017)
• Publication Date: 2017-02-19
• Subjects: Immunology -- Periodicals; Immunology -- Research -- Periodicals; 616.07905
• DOI: 10.1155/2017/3597613
• Languages: English
• ISSNs: 2314-8861

Abstract

Abstract : Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced tumors may provide an appealing promise for immunotherapy in glioma. The future of therapy for GBM will likely incorporate a combinatorial, personalized approach, including current conventional treatments, active immunotherapeutics, plus agents targeting immunosuppressive checkpoints.